Deep Track Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Deep Track Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,460,756	Closed	-$125M	–	78
2024 Q4	$125M	Sell	3,460,756 -383,144	-10%	-$13.4M	4.66%	6
2024 Q3	$123M	Buy	3,843,900 +143,900	+4%	+$5.38M	3.91%	6
2024 Q2	$139M	Buy	3,700,000 +220,147	+6%	+$9.27M	4.16%	5
2024 Q1	$171M	Sell	3,479,853 -583,823	-14%	-$27M	4.91%	1
2023 Q4	$148M	Buy	4,063,676 +517,241	+15%	+$13.5M	4.95%	2
2023 Q3	$82M	Hold	3,546,435	–	–	3.16%	11
2023 Q2	$93M	Buy	3,546,435 +446,435	+14%	+$11.7M	4.3%	9
2023 Q1	$79.8M	Sell	3,100,000 -9,886	-0.3%	-$289K	3.28%	10
2022 Q4	$80.9M	Buy	3,109,886 +740,676	+31%	+$18.2M	3.4%	10
2022 Q3	$67.6M	Buy	+2,369,210	New	+$67.9M	3.1%	8

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deep Track Capital's SWTX Position: Q1 2025 in Review

Deep Track Capital sold out of SpringWorks Therapeutics (SWTX) in Q1 2025, closing a stake of 3,460,756 shares — an estimated $125M sold.

Deep Track Capital first reported a position in SWTX in Q3 2022 and held it in 10 quarters. The position peaked at $171M in Q1 2024. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

Deep Track Capital reported no remaining SpringWorks Therapeutics position as of Q1 2025 after selling out during the quarter.
Deep Track Capital sold 3,460,756 SpringWorks Therapeutics shares in Q1 2025, an estimated $125M.
Deep Track Capital first reported a position in SpringWorks Therapeutics in Q3 2022 and held it in 10 quarters.
Deep Track Capital's SpringWorks Therapeutics position peaked at $171M in Q1 2024.
306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.